Alzheimer's disease
Conditions
Interventions
Case group:none
Heathy control group:none
Sponsors
Affiliated Hospital of Zunyi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for healthy individuals:30 healthy participants, including10 participants aged 18-39 years old, 10 participants aged 40-59 years old, and 10 participants aged 60-80 years old. There is no gender restriction. Enrollment criteria for Alzheimer's disease: (1)10 participants 40 years old = age = 59 years old, 10 participants 60 years old = age = 80 years old,; (2) regardless of gender; (3) meeting the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) diagnostic criteria for probable AD (1984); (4) the degree of the disease being mild, the total score of the Mini-mental State Examination (MMSE) total score: 21 = MMSE total score = 26 (21 = MMSE score = 22 for subjects with elementary school education); 5) Hutchinsky Ischemic Scale (HIS) total score = 4; 6) Hamilton Depression Scale/17-item version (HAMD) total score = 10; 7) Memory loss for at least 12 months with a tendency for progressive exacerbation; 8) At the time of screening A cranial MRI scan and oblique coronal hippocampal scan must be performed to support the diagnosis of Alzheimer's disease, with a Medial Temporal Atrophy Visual Rating Scale MTA classification =2; 9) No obvious neurological localization signs; 10) Subjects were elementary school educated and above, and were able to complete the cognitive function assessment and other tests as specified in the protocol; 11) Participated in the study voluntarily, and signed an informed consent form.
Exclusion criteria
Exclusion criteria: Exclusion criteria for healthy individuals: 1) Previously received cell therapy; 2) Previous or existing history of intracranial, subdural, or subarachnoid hemorrhage; 3) Subjects with baseline brain MRI showing more than four (4) cerebral microbleeds (regardless of their anatomical location or diagnostic features as "possible" or "determined") and/or one (1) or more superficial iron deposition areas, and/or evidence of previous major bleeding. MRI must include liquid attenuated inversion recovery (FLAIR) and T2 * weighted gradient echo (GRE) sequences; 4) History of cancer in the past 5 years, excluding local basal cell carcinoma or squamous cell carcinoma; 5) History of epilepsy; 6) Diagnosis of autosomal dominant inherited cerebral artery disease (CADASIL) with subcortical infarction and white matter encephalopathy; 7) History of previous or chronic cancer; 8) Patients with a history of severe cardiovascular and cerebrovascular diseases, severe liver and kidney dysfunction, or any blood related diseases; 9) Pregnant or lactating women; 10) Participated in clinical trials of other drugs (defined as receiving the investigational drug or placebo) within 3 months prior to randomization; 11) Individuals with any history of allergies; 12) History of infection in the past 4 weeks; 13) Patients who have been taking immunosuppressants or hormones for a long time in the past; 14) The researcher determines that the subjects are not suitable to participate in other situations of this clinical trial. Exclusion criteria for Alzheimer's disease individuals: 1)During screening, MRI examination showed significant focal lesions: there were more than 2 infarctions with a diameter greater than 2 cm, and there were infarctions in key areas such as thalamus, hippocampus, entorhinal cortex, paraolfactory cortex, angular gyrus, cortex, and other subcortical gray matter nuclei; Fazekas Scale classification of white matter damage = 3; 2) Previously suffered from neurological disorders (including stroke, optic neuritis, Parkinson's disease, epilepsy, etc.); 3) Psychiatric patients, according to DSM-IV-TR criteria, including schizophrenia or other psychiatric disorders, bipolar disorder, major depression or delirium; 4) Having unstable or severe heart, lung, liver, kidney, or hematopoietic system diseases; 5) There are uncorrectable visual and auditory impairments that prevent the completion of neuropsychological tests and scale assessments; 6) History of infection in the past 4 weeks; 7) Patients who have been taking immunosuppressants or hormones for a long time in the past; 8) History of previous or chronic cancer; 9) The researcher determines that the subjects are not suitable to participate in other situations of this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FPR2 expression in B cell;The effect of regulating FPR2 expression on B cell actin remodeling and BCR signaling; | — |
Countries
China
Contacts
Public Contactchang-yin Yu
Affiliated Hospital of Zunyi Medical University
Outcome results
None listed